

Benedetto Farsaci

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1569156/benedetto-farsaci-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39
papers

2,623
citations

21
h-index

51
g-index

52
ext. papers

3,139
ext. citations

6
avg, IF

4.55
L-index

#	Paper	IF	Citations
39	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1428-1439	2.2	377
38	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 942-950	2.2	175
37	Nivolumab in combination with daratumumab, with or without pomalidomide and dexamethasone, for relapsed/refractory multiple myeloma: 2 cohorts of the phase 1 CheckMate 039 safety study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS3102-TPS3102	2.2	2
36	Nivolumab for classical Hodgkin lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , 2016 , 17, 1283-94	21.7	643
35	A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039). <i>Blood</i> , 2016 , 128, 183-183	2.2	82
34	Chromosome 9p24.1/PD-L1/PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). <i>Blood</i> , 2016 , 128, 2923-2923	2.2	4
33	Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) a phase 2 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7535-7535	2.2	7
32	1370: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profiling analyses. <i>Journal of Thoracic Oncology</i> , 2016 , 11, S115-S116	8.9	8
31	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016 , 4, 755-65	12.5	25
30	Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack 2015 , 3, 52		14
29	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2015 , 1, 1087-95	13.4	58
28	Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. <i>International Journal of Cancer</i> , 2014 , 135, 862-70	7.5	4
27	Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. <i>Cancer Immunology Research</i> , 2014 , 2, 133-41	12.5	93
26	Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301) 2014 , 2,		3
25	PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients 2014 , 2,		78
24	Tumor vascular normalization as a strategy to potentiate effectiveness of therapeutic vaccines 2014 , 2,		78
23	Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. <i>Cancer Immunology Research</i> , 2014 , 2, 1090-102	12.5	51

22	Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. <i>Journal of Immunology</i> , 2014 , 192, 2622-33	5.3	21
21	Therapeutic cancer vaccines. <i>Advances in Cancer Research</i> , 2014 , 121, 67-124	5.9	49
20	PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment 2014 , 2,		9
19	NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3081-3081	2.2	5
18	Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. <i>International Journal of Cancer</i> , 2013 , 133, 624-36	7.5	170
17	Recombinant TRICOM-based Therapeutic Cancer Vaccines: Lessons Learned 2013 , 309-331		1
16	Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival 2013 , 1,		78
15	Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells 2013 , 1,		78
14	Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. <i>Clinical Cancer Research</i> , 2013 , 19, 6205-18	12.9	65
13	Effects of conventional therapeutic interventions on the number and function of regulatory T cells. <i>Onc Immunology</i> , 2013 , 2, e27025	7.2	105
12	The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. <i>Seminars in Oncology</i> , 2012 , 39, 323-39	5.5	107
11	Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. <i>International Journal of Cancer</i> , 2012 , 130, 1948-59	7.5	99
10	Distinct effects of saracatinib on memory CD8+ T cell differentiation. <i>Journal of Immunology</i> , 2012 , 188, 4323-33	5.3	11
9	An alternative dielectric model for low and high frequencies: A non-equilibrium thermodynamic approach. <i>Journal of Non-Equilibrium Thermodynamics</i> , 2012 , 37,	3.8	10
8	Design, development, and translation of poxvirus-based vaccines for cancer 2011 , 56-77		1
7	Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. <i>International Journal of Cancer</i> , 2010 , 127, 1603-13	7.5	35
6	Abstract 4790: Docetaxel modulates phenotype of human carcinoma cells, including drug-resistant tumor cells, resulting in enhanced killing by CTLs 2010 ,		2
5	TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 1809-18	7.4	23

4	Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cells in the infused suspension and patient age. <i>Cytotherapy</i> , 2007 , 9, 348-55	4.8	42
3	Failure of CD34+ Mobilization in AML Patients Is Associated to an Abnormally High Chemosensitivity of Non Leukemic CFU-GM.. <i>Blood</i> , 2007 , 110, 2849-2849	2.2	
2	Adverse Events after Infusions of Cryopreserved Hematopoietic Stem Cells Depend on Non-Mononuclear Cell in Infused Suspension and on Patient Age.. <i>Blood</i> , 2006 , 108, 5244-5244	2.2	
1	CD34+ selected haematopoietic stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure. <i>Bone Marrow Transplantation</i> , 2005 , 35, 521-2; author reply 522	4.4	7